Dec 13, 2013 by Jan RobisonGilead Sciences' $1,000 Per Day Sovaldi Pills Ready to LaunchLate Friday, the FDA approved Gilead Sciences' much awaited hepatitis C treatment Sovaldi. How will Gilead shares react in the coming weeks?
Dec 10, 2013 by Jan RobisonEli Lilly: Fasten Your Seat Belts for a Bumpy RideEli Lilly is facing a perfect storm. Its lead product, the antidepressant Cymbalta will lose its U.S. patent exclusivity this week while its late stage phase 3 wildcating has been producing dry holes.
Dec 9, 2013 by Jan RobisonOrexigen Therapeutics: Light at the End of the Tunnel?Orexigen Therapeutics announces successful interim results for its lead product candidate Contrave followed by the potentially share dilutive announcement of $100 million convertible senior notes offering. Which way should the stock go?
Nov 20, 2013 by Jan RobisonCelgene's Product Portfolio Performance Boosts Valuation ProspectsCelgene, which has almost doubled in value since the begining of the year, reported a strong 3rd quarter performance, raised its EPS guidance for the year and is poised for another exceptional year in 2014.
Nov 20, 2013 by Jan RobisonLooking at the Future of Salix PharmaceuticalsLet's dive deeper at Salix Pharmaceuticals' acquisition of Santarus and its lead drug Uceris.
Nov 11, 2013 by Jan RobisonSeattle Genetics Is Down but Not OutSeattle Genetics share price has been trending lower lately due to adverse side effects experienced by some patients undergoing clinical trials with the company’s lead product Adcetris. Since long term prospects look bright forSeattle, this could be a nice chance for value investors to enter the stock.
Oct 25, 2013 by Jan RobisonRegeneron's Eylea Is on Its Way Toward Blockbuster StatusRegeneron's Eylea U.S. sales are expected to reach $1.3 billion in 2013, qualifying it for a blockbuster status after just two full years on the market.
